Stay updated on Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial
Sign up to get notified when there's something new on the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page.

Latest updates to the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page
- ChecktodayChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed study objectives and inclusion/exclusion criteria for a clinical trial on Y90 radioembolization combined with nivolumab for hepatocellular carcinoma. Additionally, the principal investigator's name has been updated.SummaryDifference50%
- Check22 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for January 6, 2025, while a date of March 25, 2025, has been removed.SummaryDifference0.4%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check65 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check79 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page.